Adenosine A2A agonists as therapy for glomerulonephritis

Slides:

Advertisements

Similar presentations

Renal involvement in hepatitis C infection: Cryoglobulinemic glomerulonephritis Giuseppe D’Amico Kidney International Volume 54, Issue 2, Pages

Advertisements

Current status of end-stage renal disease care in India and Pakistan

Michael D. Gautreaux, Barry I. Freedman Kidney International

A powerful new agonist: flooding the system with growth hormone

Volume 78, Issue 2, Pages (July 2010)

Volume 81, Issue 1, Pages 5-6 (January 2012)

Anemia management in chronic kidney disease

Mitchell H. Rosner, W. Kline Bolton Kidney International

Bettina Haslinger-Löffler Kidney International

Stem cells for kidney repair: useful tool for acute renal failure?

Cell signaling and cancer

Shining light on vitamin D trials in chronic kidney disease

Zaccaria Ricci, Claudio Ronco, Sergio Picardo Kidney International

Volume 80, Issue 10, Pages (November 2011)

Burden of chronic kidney disease: North Africa

Regulatory T cells and cancer: an undesired tolerance

Steroid-free maintenance immunosuppression in kidney transplantation: is it time to consider it as a standard therapy? Fu L. Luan, Diane E. Steffick,

Volume 84, Issue 2, Pages (August 2013)

End-stage renal disease in living kidney donors

Volume 77, Issue 1, Pages 5-6 (January 2010)

Comorbidity and confounding in end-stage renal disease

Early mortality in dialysis and adequacy of predialysis renal care: the picture is more complex than we thought Nicolas Rognant, Maurice Laville Kidney.

Volume 74, Issue 3, Pages (August 2008)

The new role of calcimimetics as vasculotropic agents

Lipid redistribution in renal dysfunction

Volume 82, Issue 8, Pages (October 2012)

Volume 70, Issue 11, Pages (December 2006)

Volume 86, Issue 2, Pages (August 2014)

Reciprocal functions of hepatocyte growth factor and transforming growth factor-β1 in the progression of renal diseases: A role for CD44? Sandrine Florquin,

Harnessing regulatory T cells for therapeutic purposes

Volume 71, Issue 6, Pages (March 2007)

Frank Eitner, Jürgen Floege Kidney International

Modulating kidney transplant interstitial fibrosis and tubular atrophy: is the RAAS an important target? Hatem Amer, Matthew D. Griffin Kidney International

Volume 76, Issue 6, Pages (September 2009)

IgG4-related tubulointerstitial nephritis

Extracorporeal therapy in sepsis: are we there yet?

Volume 69, Issue 12, Pages (June 2006)

Volume 69, Issue 3, Pages (February 2006)

Volume 85, Issue 5, Pages (May 2014)

Volume 87, Issue 1, Pages (January 2015)

Atrial fibrillation in end-stage renal disease: an emerging problem

CD4+ T cells: a potential player in renal fibrosis

Counteracting progression of renal disease: A look into the future

Nephrology Crossword: Glomerulonephritis

Volume 80, Issue 4, Pages (August 2011)

Unilateral renal cystic disease

Prehypertension: is it relevant for nephrologists?

Volume 73, Issue 9, Pages (May 2008)

Volume 82, Issue 9, Pages (November 2012)

Volume 74, Issue 9, Pages (November 2008)

Stephen O'Neill, Jeremy Hughes Kidney International

Does equal care give equal outcomes?

Volume 83, Issue 5, Pages (May 2013)

ANCA-associated glomerulonephritis in the very elderly

Charles A. Herzog Kidney International

Is complement a target for therapy in renal disease?

David A. Ferenbach, David C. Kluth, Jeremy Hughes Kidney International

Volume 70, Issue 3, Pages (August 2006)

Volume 83, Issue 3, Pages (March 2013)

Kathryn J. Wiggins, Darren J. Kelly Kidney International

Volume 75, Issue 7, Pages (April 2009)

Membranous nephropathy: recent travels and new roads ahead

Volume 76, Issue 9, Pages (November 2009)

Hisataka Kobayashi, Peter L. Choyke Kidney International

The international realities of live donor kidney transplantation

Volume 75, Issue 8, Pages (April 2009)

Volume 72, Issue 8, Pages (October 2007)

The Ebf1 knockout mouse and glomerular maturation

Ronen Levi, Justin Silver Kidney International

Epidemiologic data of renal diseases from a single unit in China: Analysis based on 13,519 renal biopsies Lei-Shi Li, Zhi-Hong Liu Kidney International

Presentation transcript:

Adenosine A2A agonists as therapy for glomerulonephritis David A. Ferenbach, Jeremy Hughes Kidney International Volume 80, Issue 4, Pages 329-331 (August 2011) DOI: 10.1038/ki.2011.167 Copyright © 2011 International Society of Nephrology Terms and Conditions

Figure 1 Schematic diagram illustrating the diverse reported cellular targets of pharmacological A2AR activation in the immune system and the kidney that may be relevant to outcome in inflammatory renal disease. Blue arrows indicate documented anti-inflammatory or pro-cell-survival actions of A2AR activation. The red arrow indicates the positive impact of thrombospondin-1 (TSP-1) on the levels of bioactive transforming growth factor-β (TGF-β). Black lines indicate effects of A2AR agonism in anti–glomerular basement membrane disease as reported by Garcia et al.2 NK, natural killer; TIMP-1, tissue inhibitor of metallproteinase-1. Kidney International 2011 80, 329-331DOI: (10.1038/ki.2011.167) Copyright © 2011 International Society of Nephrology Terms and Conditions